Advertisement
| car t cell therapy for ovarian cancer: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t cell therapy for ovarian cancer: Ovarian Cancer Immunotherapy Samir A. Farghaly, 2018-08-31 Ovarian Cancer Immunotherapy provides a broad overview of several aspects of basic sciences, and clinical and therapeutic aspects of immunotherapy for ovarian cancer, as well as state-of-the-art information on molecular genetics and biology. Chapters are written by a team of expert contributors from around the world and explore topics such as antibody therapeutics for ovarian carcinoma, emerging serum biomarkers, ovarian cancer immunity, adoptive cell immunotherapy, the biology of dendritic cells, the role of growth factors, and more. Readers will also gain a better understanding of the molecular and cellular events that underlie ovarian cancer immunology. This book is an ideal resource for clinicians, basic medical scientists, graduate basic medical science students, and medical students caring for patients with ovarian cancer, including attending surgeons and physicians, and clinical fellows and residents in the disciplines of gynecologic oncology, medical oncology, and surgical oncology. |
| car t cell therapy for ovarian cancer: Diagnosis and Management of Ovarian Disorders Albert Altchek, Liane Deligdisch, Nathan Kase, 2003-09-04 This updated second edition of Diagnosis and Management of Ovarian Disorders provides thorough, yet succinct insight into the ever-changing realm of ovarian disorders. It presents a novel multidisciplinary approach to the subject as described by clinicians, surgeons, pathologists, basic scientists and related medical researchers. Topics covered include reproductive technology, early diagnosis of ovarian cancer, and management of menopause among others. The breadth of information provided by this book will appeal to clinicians and researchers involved in the study and treatment of ovarian disorders.KEY FEATURES* Includes updated information on early diagnosis of ovarian cancer* Reviews new diagnostic techniques for ovarian disorders* Discusses latest information on reproductive technology* Presents translational treatment linking laboratory research with clinical medicine |
| car t cell therapy for ovarian cancer: Ovarian Cancers National Academies of Sciences, Engineering, and Medicine, Institute of Medicine, Board on Health Care Services, Committee on the State of the Science in Ovarian Cancer Research, 2016-04-25 In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers. |
| car t cell therapy for ovarian cancer: Clinical Gynecology Eric J. Bieber, Joseph S. Sanfilippo, Ira R. Horowitz, Mahmood I. Shafi, 2015-04-23 Written with the busy practice in mind, this book delivers clinically focused, evidence-based gynecology guidance in a quick-reference format. It explores etiology, screening, tests, diagnosis, and treatment for a full range of gynecologic health issues. The coverage includes the full range of gynecologic malignancies, reproductive endocrinology and infertility, infectious diseases, urogynecologic problems, gynecologic concerns in children and adolescents, and surgical interventions including minimally invasive surgical procedures. Information is easy to find and absorb owing to the extensive use of full-color diagrams, algorithms, and illustrations. The new edition has been expanded to include aspects of gynecology important in international and resource-poor settings. |
| car t cell therapy for ovarian cancer: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| car t cell therapy for ovarian cancer: Immuno-oncology Olivier Michielin, George Coukos, 2015 Over the last decade, immuno-oncology has witnessed an astonishing pace of discovery and innovation translating into unprecedented successes in the clinical setting, arguably representing one of the most profound and transforming revolution in the history of cancer therapy. This book provides a concise and accurate outline of the main developments in major tumor types including melanoma, lung, breast, brain and renal cell cancers. In addition, transversal chapters that describe the commonalities of some of the therapeutic strategies are provided to cover topics like immune checkpoint biology, T cell engineering or rational combination therapies. Each chapter has been authored by senior key opinion leaders in their respective fields to provide the most up-to-date view on cancer immuno-oncology. To reflect on the key translational aspect of immuno-oncology, all chapters are making explicit connections between basic science discoveries and the resulting translational therapeutic strategies. Immuno-Oncology will be an invaluable source of information for scientists interested in the translation of basic immunology into the clinical practice, as well as for clinician interested in deepening their knowledge of current and upcoming immune strategies in the fight against cancers. |
| car t cell therapy for ovarian cancer: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| car t cell therapy for ovarian cancer: Protein Engineering Huimin Zhao, 2021-08-23 A one-stop reference that reviews protein design strategies to applications in industrial and medical biotechnology Protein Engineering: Tools and Applications is a comprehensive resource that offers a systematic and comprehensive review of the most recent advances in the field, and contains detailed information on the methodologies and strategies behind these approaches. The authors—noted experts on the topic—explore the distinctive advantages and disadvantages of the presented methodologies and strategies in a targeted and focused manner that allows for the adaptation and implementation of the strategies for new applications. The book contains information on the directed evolution, rational design, and semi-rational design of proteins and offers a review of the most recent applications in industrial and medical biotechnology. This important book: Covers technologies and methodologies used in protein engineering Includes the strategies behind the approaches, designed to help with the adaptation and implementation of these strategies for new applications Offers a comprehensive and thorough treatment of protein engineering from primary strategies to applications in industrial and medical biotechnology Presents cutting edge advances in the continuously evolving field of protein engineering Written for students and professionals of bioengineering, biotechnology, biochemistry, Protein Engineering: Tools and Applications offers an essential resource to the design strategies in protein engineering and reviews recent applications. |
| car t cell therapy for ovarian cancer: Surgery for Ovarian Cancer Robert E. Bristow, Beth Y. Karlan, Dennis S. Chi, 2019-02-21 Updated and expanded, the third edition of Surgery for Ovarian Cancer focuses on essential techniques for the effective management of ovarian cancer. It reflects the most contemporary science and surgical applications for the management of patients with ovarian cancer and related peritoneal surface malignancies. This new edition takes a step-by-step approach and includes new intraoperative photographs and videos illustrating surgical procedures. It is principally devoted to the technical aspects of cytoreductive surgery, with chapters divided according to anatomic region. The chapters cover relevant anatomical considerations, surgical challenges specific to each region, and operative approaches and techniques favored by the authors. The list of contributing authors has been expanded from the previous edition and includes international and world-renowned experts from the fields of gynecologic oncology and surgical oncology. The topics of minimally invasive surgery, secondary cytoreduction, palliative surgery, and postoperative care are also covered in detail. New to the third edition are chapters on preoperative risk stratification, regional therapeutics and peritonectomy procedures, and quality assurance relating to ovarian cancer surgery. This comprehensive text is essential reading for all practitioners working with patients with ovarian cancers. |
| car t cell therapy for ovarian cancer: Heparanase Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan, 2020-04-09 Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology. |
| car t cell therapy for ovarian cancer: Gynaecological Oncology Mahmood I. Shafi, Helena M. Earl, Li Tee Tan, 2009-12-03 Providing a thorough and up-to-date overview of the full range of gynaecological cancers, Gynaecological Oncology is a concise introduction, particularly useful for trainees working towards postgraduate examinations. The first section includes introductory chapters on epidemiology, screening and prevention, imaging, pathology, surgery, radiation therapy, chemotherapy, and palliation. The second part of the book covers the gynaecological cancer types in turn; each chapter following a similar format looking at clinical issues, staging, and principles of management. Where appropriate, flow-charts and diagrams are used to help the reader assimilate complex information. A chapter is devoted to decision-making, addressing those issues clinicians and women face when deciding on optimal management in given clinical scenarios. The book is practically based and is enhanced by highlighting learning points, management algorithms and clinical images. This is an invaluable resource for all doctors and allied health professionals dealing with women with gynaecological cancers. |
| car t cell therapy for ovarian cancer: Co-signal Molecules in T Cell Activation Miyuki Azuma, Hideo Yagita, 2019-11-22 This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science. |
| car t cell therapy for ovarian cancer: The Cancer Stem Cell Niche Susie Nilsson, 2021-02-09 The Cancer Stem Cell Niche, Volume Five in the Advances in Stem Cells and their Niches series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Acute lymphoblastic leukemia and the bone marrow microenvironment, Stem cell niches in bone and their roles in cancer metastasis, The role of vasculature in cancer stem cell niches, The lung cancer stem cell niche, The prostate cancer stem cell niche: Genetic drivers and therapeutic approaches, Impact of prostate cancer stem cell niches on prostate cancer tumorigenesis and progression, The testicular cancer stem cell niche. Provides the authority and expertise of leading contributors from an international board of authors Presents the latest release in the Advances in Stem Cells and their Niches series Includes the latest information on the Cancer Stem Cell Niche |
| car t cell therapy for ovarian cancer: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| car t cell therapy for ovarian cancer: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| car t cell therapy for ovarian cancer: Treatment of Leukemia and Lymphoma David A. Scheinberg, Joseph G. Jurcic, 2004-10-30 New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.* Provides an up-to-date, state of the art discussion of a rapidly changing field * Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells * Written by international experts in each of the fields |
| car t cell therapy for ovarian cancer: Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications Susan C. Frost, Robert McKenna, 2013-10-22 The study of carbonic anhydrase has spanned multiple generations of scientists. Carbonic anhydrase was first discovered in 1932 by Meldrum and Roughton. Inhibition by sulfanilamide was shown in 1940 by Mann and Keilin. Even Hans Krebs contributed to early studies with a paper in 1948 showing the relationship of 25 different sulfonamides to CA inhibition. It was he who pointed out the importance of both the charged and uncharged character of these compounds for physiological experiments. The field of study that focuses on carbonic anhydrase (CA) has exploded in recent years with the identification of new families and isoforms. The CAs are metalloenzymes which are comprised of 5 structurally different families: the alpha, beta, gamma, and delta, and epsilon classes. The alpha class is found primarily in animals with several isoforms associated with human disease. The beta CAs are expressed primarily in plants and are the most divergent. The gamma CAs are the most ancient. These are structurally related to the beta CAs, but have a mechanism more similar to the alpha CAs. The delta CAs are found in marine algae and diflagellates. The epsilon class is found in prokaryotes in which it is part of the carboxysome shell perhaps supplying RuBisCO with CO2 for carbon fixation. With the excitement surrounding the discovery of disease-related CAs, scientists have redoubled their efforts to better understand structure-function relationships, to design high affinity, isotype-specific inhibitors, and to delineate signaling systems that play regulatory roles over expression and activity. We have designed the book to cover basic information of mechanism, structure, and function of the CA families. The authors included in this book bring to light the newest data with regard to the role of CA in physiology and pathology, across phylums, and in unique environmental niches. |
| car t cell therapy for ovarian cancer: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| car t cell therapy for ovarian cancer: Brain Tumor Immunotherapy Linda M. Liau, Donald P. Becker, Timothy F. Cloughesy, Darell D. Bigner, 2000-11-10 An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics. |
| car t cell therapy for ovarian cancer: Oxygen Sensing , 2004-05-10 The ability of cells to sense and respond to changes in oxygenation underlies a multitude of developmental, physiological, and pathological processes. This volume provides a comprehensive compendium of experimental approaches to the study of oxygen sensing in 48 chapters that are written by leaders in their fields. |
| car t cell therapy for ovarian cancer: Guidelines for Preparing Patent Landscape Reports World Intellectual Property Organization, 2015-08-24 These Guidelines are designed both for general users of patent information, as well as for those involved in producing Patent Landscape Reports (PLRs). They provide step-by-step instructions on how to prepare a PLR, as well as background information such as objectives, patent analytics, concepts and frameworks. |
| car t cell therapy for ovarian cancer: The Breakthrough Charles Graeber, 2015-12-01 Follow along as this New York Times bestselling author details the astonishing scientific discovery of the code to unleashing the human immune system to fight in this captivating and heartbreaking book (The Wall Street Journal). For decades, scientists have puzzled over one of medicine's most confounding mysteries: Why doesn't our immune system recognize and fight cancer the way it does other diseases, like the common cold? As it turns out, the answer to that question can be traced to a series of tricks that cancer has developed to turn off normal immune responses -- tricks that scientists have only recently discovered and learned to defeat. The result is what many are calling cancer's penicillin moment, a revolutionary discovery in our understanding of cancer and how to beat it. In The Breakthrough, New York Times bestselling author of The Good Nurse Charles Graeber guides readers through the revolutionary scientific research bringing immunotherapy out of the realm of the miraculous and into the forefront of twenty-first-century medical science. As advances in the fields of cancer research and the human immune system continue to fuel a therapeutic arms race among biotech and pharmaceutical research centers around the world, the next step -- harnessing the wealth of new information to create modern and more effective patient therapies -- is unfolding at an unprecedented pace, rapidly redefining our relationship with this all-too-human disease. Groundbreaking, riveting, and expertly told, The Breakthrough is the story of the game-changing scientific discoveries that unleash our natural ability to recognize and defeat cancer, as told through the experiences of the patients, physicians, and cancer immunotherapy researchers who are on the front lines. This is the incredible true story of the race to find a cure, a dispatch from the life-changing world of modern oncological science, and a brave new chapter in medical history. |
| car t cell therapy for ovarian cancer: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| car t cell therapy for ovarian cancer: Biomechanics in Oncology Cheng Dong, Nastaran Zahir, Konstantinos Konstantopoulos, 2018-10-27 This book covers multi-scale biomechanics for oncology, ranging from cells and tissues to whole organ. Topics covered include, but not limited to, biomaterials in mechano-oncology, non-invasive imaging techniques, mechanical models of cell migration, cancer cell mechanics, and platelet-based drug delivery for cancer applications. This is an ideal book for graduate students, biomedical engineers, and researchers in the field of mechanobiology and oncology. This book also: Describes how mechanical properties of cancer cells, the extracellular matrix, tumor microenvironment and immuno-editing, and fluid flow dynamics contribute to tumor progression and the metastatic process Provides the latest research on non-invasive imaging, including traction force microscopy and brillouin confocal microscopy Includes insight into NCIs’ role in supporting biomechanics in oncology research Details how biomaterials in mechano-oncology can be used as a means to tune materials to study cancer |
| car t cell therapy for ovarian cancer: Successes and Challenges of NK Immunotherapy Benjamin Bonavida, Anahid Jewett, 2021-06-23 Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy describes the unique therapeutic applications of NK cells to fight cancers and eliminate the bulk and subset of cancer stem cells responsible for metastasis, relapse and recurrences. The book provides information on the development, engineering, mechanisms of action, response to various preclinical models, and applications in various clinical trials. Sections cover the development of highly engineered cytotoxic NK cells, their mechanisms of action, preclinical and clinical applications, the development and application of CAR-NK cells, and new NK-drug conjugates, also emphasizing that activated NK cells can target and kill highly resistant cancer stem cells. Written by the leading experts on NK immunotherapy worldwide, this is a valuable resource for researchers, clinicians and members of the biomedical field who are interested in understanding novel and efficient therapies to fight cancers. - Discusses the unique developmental applications of NK immunotherapy against cancers, which differs greatly from other types of immunotherapies - Provides up-to-date and highly relevant information through chapters written by the leading researchers in the field - Presents a significant number of schematic diagrams for easy understanding and reproducibility |
| car t cell therapy for ovarian cancer: Bioreactor Systems for Tissue Engineering Cornelia Kasper, Martijn van Griensven, Ralf Pörtner, 2009-02-03 The editors of this special volume would first like to thank all authors for their excellent contributions. We would also like to thank Prof. Dr. Thomas Scheper, Dr. Marion Hertel and Ulrike Kreusel for providing the opportunity to compose this volume and Springer for organizational and technical support. Tissue engineering represents one of the major emerging fields in modern b- technology; it combines different subjects ranging from biological and material sciences to engineering and clinical disciplines. The aim of tissue engineering is the development of therapeutic approaches to substitute diseased organs or tissues or improve their function. Therefore, three dimensional biocompatible materials are seeded with cells and cultivated in suitable systems to generate functional tissues. Many different aspects play a role in the formation of 3D tissue structures. In the first place the source of the used cells is of the utmost importance. To prevent tissue rejection or immune response, preferentially autologous cells are now used. In particular, stem cells from different sources are gaining exceptional importance as they can be differentiated into different tissues by using special media and supplements. In the field of biomaterials, numerous scaffold materials already exist but new composites are also being developed based on polymeric, natural or xenogenic sources. Moreover, a very important issue in tissue en- neering is the formation of tissues under well defined, controlled and reprod- ible conditions. Therefore, a substantial number of new bioreactors have been developed. |
| car t cell therapy for ovarian cancer: Adoptive Immunotherapy Burkhard Ludewig, Matthias W. Hoffmann, 2008-02-02 An authoritative collection of optimal techniques for producing and characterizing the immunologically active cells and effector molecules now gaining wide use in the clinical treatment of patients. Taking advantage of the latest technologies, the authors present readily reproducible experimental protocols for the study of dendritic cells, T cells, monoclonal antibodies, and bone marrow transplantation. The emphasis is on preclinicical and clinical applications and on the progress of selected approaches in clinical trials. Additional chapters cover the molecular definition of target antigens, mathematical modeling approaches to immunotherapy, and the utilization of regulatory T cells. The protocols make it possible to study the adoptive transfer of tailored antigen-specific immune cells and to improve the clinical application of adoptive immunotherapy. |
| car t cell therapy for ovarian cancer: Natural Killer Cells Srinivas S. Somanchi, 2016-05-13 This volume contains collection of Natural Killer Cell methodologies relevant for both basic and translational research. These methodologies present new developments in the natural killer (NK) cell field, such as understanding the influence of NK cells metabolism on its function, identifying complexity of NK cell subsets through mass cytometry, and determining the emergence of memory NK cells in murine model of MCMV infection. Methods that study NK cell migration and cytotoxicity through endpoint analysis or live single cell imaging are also discussed. Chapters also describe methods pertaining to translational application of NK cells, such as ex vivo expansion of NK cells on K562 cell lines genetically modified to express either membrane bound IL-15 or membrane bound IL-21, large scale NK cell culture, current techniques for engineering NK cells to express chimeric antigen receptors or chemokine receptors using retroviral vectors, electroporation of mRNA, and the natural phenomenon of trogocytosis. Written in the highly successful Methods in Molecular Biology series format, these chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, Natural Killer Cells: Methods and Protocols is a valuable resource for researchers who not only want to understand mechanisms that govern NK cell behavior and diversity, but also for those who want to understand how to systematically evaluate NK cells for adoptive immunotherapy applications. |
| car t cell therapy for ovarian cancer: Central Nervous System Metastases Manmeet Ahluwalia, Philippe Metellus, Riccardo Soffietti, 2019-11-05 This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors. |
| car t cell therapy for ovarian cancer: Tumor Microenvironment Alexander Birbrair, 2020-06-25 Revealing essential roles of the tumor microenvironment in cancer progression, this book provides a comprehensive overview of the latest research in the field. A variety of topics are covered, including metabolism in the tumor microenvironment, stellate cells and endothelial progenitors in the tumor microenvironment, as well as the effects of HIV, viral hepatitis, and inflammation in the tumor microenvironment, and more. Taken alongside its companion volumes, Tumor Microenvironment: State of the Science updates us on what we know about various aspects of the tumor microenvironment, as well as future directions. This book is essential reading for advanced cell biology and cancer biology students as well as researchers seeking an update on research in the tumor microenvironment. |
| car t cell therapy for ovarian cancer: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| car t cell therapy for ovarian cancer: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice MiKaela M. Olsen, Kristine B. LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2022 Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice-- |
| car t cell therapy for ovarian cancer: Patient Derived Tumor Xenograft Models Rajesh K. Uthamanthil, Peggy Tinkey, Elisa de Stanchina, 2016-10-25 Patient Derived Tumor Xenograft Models: Promise, Potential and Practice offers guidance on how to conduct PDX modeling and trials, including how to know when these models are appropriate for use, and how the data should be interpreted through the selection of immunodeficient strains. In addition, proper methodologies suitable for growing different type of tumors, acquisition of pathology, genomic and other data about the tumor, potential pitfalls, and confounding background pathologies that occur in these models are also included, as is a discussion of the facilities and infrastructure required to operate a PDX laboratory. |
| car t cell therapy for ovarian cancer: Gynaecological Cancers Risk Ranjit Manchanda, 2022-01-25 The International Agency for Research on Cancer suggests that the burden of women's cancers including breast, ovarian, and womb will rise by 50% over the next 20 years. It is essential for us to improve early diagnosis and prevention of these cancers in our health systems. The last decade has seen significant strides in our ability to understand and predict a woman's risk of these cancers and offer personalized medicine approaches for risk management. There have been improvements in identifying individuals at increased risk, as well as implementing and evaluating strategies for screening and prevention. In this special collection, we bring together 16 articles from leading scientists and researchers. These capture some of the important advances observed in estimating cancer risk, providing genetic testing, offering risk management to those at increased risk, as well as screening and prevention of breast, ovarian, and womb cancers in women. This makes an important contribution to the rapidly advancing knowledge base across the area of personalized medicine and precision prevention of ovarian, endometrial, and breast cancers. |
| car t cell therapy for ovarian cancer: Mammalian Cell Engineering Ryosuke Kojima, 2022-07-21 This volume explores the latest engineering methods of mammalian cells that are useful for controlling the performance of engineered mammalian cells for future cell-based therapeutics and for better understanding of complex biological systems. The chapters in this book are organized into five parts. Part One described methods to engineer mammalian cells to sense biologically relevant inputs, such as cell contacts and soluble proteins. Part Two looks at techniques to engineer mammalian cells to sense artificial inputs, such as light and ultrasound. Part Three provides cutting-edge CRISPR-Cas-based methods to carry out highly multiplexed genome editing and spatiotemporally controlled genome editing. Part Four discusses ways to control and engineer biological events in mammalian cells in combination with chemical compounds and systems. Part Five explores techniques to engineer specific mammalian cells in targeted manners. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Comprehensive and authoritative, Mammalian Cell Engineering: Methods and Protocols is a valuable resource that allows scientists to successfully carry out their research, thus ultimately contributing to the future advancement of this field. |
| car t cell therapy for ovarian cancer: Tumour Angiogenesis R. John Bicknell, Claire E. Lewis, Napoleone Ferrara, 1997 Tumour Angiogenesis is the first comprehensive book to cover all areas of this rapidly expanding research area. Each chapter is written by world experts in the field and topics covered include in vivo models, mechanisms, inhibition, and the role of macrophages, cytokines, proteases,extracellular matrix components, nitric oxide, prostanoids and oncogenes/tumour suppressor genes in angiogenesis. Other chapters examine the role of specific growth factors in angiogenesis - these include vascular endothelial growth factor, the basic fibroblast growth factor family, transforminggrowth factor-beta, tumour necrosis factor-alpha, platelet-derived endothelial cell growth factor/thymidine phosphorylase and pleiotrophin and related molecules. Clinical issues are addressed in chapters that deal with the prognostic and predictive value of tumour microvessel density and thetherapeutic significance of microregional blood flow. The two final chapters examine the feasibility of targeting tumour vasculature using either antibodies or gene therapy. |
| car t cell therapy for ovarian cancer: Volume 1 , Advances in Oncology Leonidas C. Platanias, 2021-05 This premier volume of Advances in Oncology highlights the latest findings and updates within the cancer field each year for the practicing oncologist. Advances in Oncology publishes the most current thinking and recent advances from the voice of a truly distinguished editorial board, including Editor-in-Chief Leonidas C. Platanias, who identify current advances and breakthroughs in the field and invite specialists to contribute original articles on these topics. Topics discussed in this first volume are within the areas of radiation oncology, surgical oncology, medical oncology, gynecologic oncology, pediatric oncology, neuro-oncology, hemato-oncology, uro-oncology, and gastrointestinal oncology. This volume will appeal to all practicing oncologists and will inform and enhance clinical practice. |
| car t cell therapy for ovarian cancer: Novel Designs of Early Phase Trials for Cancer Therapeutics Shivaani Kummar, Chris Takimoto, 2018-05-26 Novel Designs of Early Phase Trials for Cancer Therapeutics provides a comprehensive review by leaders in the field of the process of drug development, the integration of molecular profiling, the changes in early phase trial designs, and endpoints to optimally develop a new generation of cancer therapeutics. The book discusses topics such as statistical perspectives on cohort expansions, the role and application of molecular profiling and how to integrate biomarkers in early phase trials. Additionally, it discusses how to incorporate patient reported outcomes in phase one trials. This book is a valuable resource for medical oncologists, basic and translational biomedical scientists, and trainees in oncology and pharmacology who are interested in learning how to improve their research by using early phase trials. |
| car t cell therapy for ovarian cancer: Take Control of Your Health Kendra Degen Pearsall, 2007 |
r/Cars - For Car Enthusiasts - Reddit
r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY guides, advice, stories, …
Former CarMax employee here. If you plan to go in for an ... - Reddit
Feb 3, 2021 · Where younger an estimated value and when you come in our car buyer puts in his notes and we show you side by side. Where you thought you were and didn't mention that …
How much do car salesmen REALLY make? : r/askcarsales - Reddit
Apr 26, 2022 · Is 6 figures in car sales the norm? EDIT: 25M, single, no kids. Currently in civil engineering with $78k salary in LCOL area (central texas). Seems like folks are making well …
Hoseheadforums.com Home
Aug 17, 2013 · Bodnar Motorsports building new car for 2019 viewed (10751) Wicked Energy Gum to Sponsor the Northwest Focus Midget Series viewed (8765) Heartland Motorsports Park …
best places to search for used cars : r/cars - Reddit
Sep 7, 2018 · r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY …
Car dealership scratch-off mailer scam (Update) : r/Scams - Reddit
Mar 12, 2019 · I posted a couple of days ago about a scratch-off contest mailer that I had received from a local car dealership. My "game piece" seemed to indicate that I had won the Grand …
Nothing Under - Reddit
r/NothingUnder: Dresses and clothing with nothing underneath. Women in outfits perfect for flashing, easy access, and teasing men.
What’s the best auto insurance? : r/Insurance - Reddit
I also know that being young and driving a newer car is the reason behind all this, but any advice/tips about all this is much needed! Is the monthly rate really normal for someone my …
HoseHeads Sprint Car General Forum - Oval Track Racing Forums
4 days ago · Forum: HoseHeads Sprint Car General Forum Moderators: dirtonly / dmantx / hosehead First
I've been scouring the internet for a working download link to
Aug 26, 2023 · 31 votes, 30 comments. 36K subscribers in the E90 community. Hub for all BMW 3 series, 2006-2013. Anyone is welcome!
CAR T cell combination therapies to treat cancer - Cell Press
Various therapies under investigation in combination with CAR T cell therapy within clinical trials. These agents, through diverse mechanisms, offer potential ... Pancreatic cancer, ovarian …
Tandem CAR-T cells targeting FOLR1 and MSLN enhance the …
Given the heterogeneity of solid tumors, single -target CAR -T cell therapy often leads to recurrence, especially in ovarian cancer (OV). H ere, we constructed a Tandem -CAR …
Dominant-negative transforming growth factor-β receptor …
of ovarian cancer, adoptive T-cell therapy has received increasing attention as an immunotherapy strategy for ovarian cancer [10]. Patients treated with infiltrating T ... of ovarian cancer cells. …
Opportunities and challenges of combining adoptive cellular …
antigen receptor (CAR)-T cells, T cell receptor (TCR) T cells, tumor-infiltrating lymphocytes (TILs), and both unmodified and modified/ expanded natural killer (NK) cells. Thus far, …
Phase I clinical safety and efficacy observation of αPD-1 …
na; Medical Center of Shanghai Cell Therapy Group, Shanghai, China; Shanghai Cell Therapy Group, Shanghai, China; Department of Oncology, Shanghai Tenth People’s Hospital, Tongji …
Efficacy and safety of novel multiple-chain DAP-CAR-T cells …
cells associated with CAR-T cell infusion. sequencing analysis indicated that KT032 CAR-T cell infusion could recruit more immune cells and temporarily remodel the TME. Conclusions Our …
Step further towards targeted senolytic therapy: therapeutic …
of uPAR-CAR T cells against ovarian cancer cells in vitro. None-theless, investigating CAR T-cell therapy in non-oncology study is rare, and certainly not in senescence-associated pathologies. …
Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via …
domain (TAG72-BBζ). TAG72-BBζ CAR T cells showed potent antigen-dependent cytotoxicity and cytokine production against multiple TAG72+ ovarian cancer cell lines and patient-derived …
Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy - Cell …
domains, usually derived from T cell re-ceptor signaling moieties (Sadelain et al., 2017). Antigen binding triggers an intra-cellular signaling cascade and subse-quent activation of the immune …
Novel Immunotherapy Approaches and Cellular-based …
CAR T-cell Therapy for Ovarian Cancer . Adoptive Cell Therapy: TIL ... Upcoming Adoptive Cell Therapy Trials at MDACC • 2017-0505 (NCT03108495) A Phase 2, Multicenter Study to …
CANCER copyright © 2025 The Mitigating T cell DNA …
May 7, 2025 · CAR T cell therapy has the potential to address the immunosuppres-sive TME and inadequate CAR T cell infiltration into the tumor, po-tentially leading to active monitoring and …
B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects …
translating B7-H3-targeted CAR-T cell therapy into clinical practice. INTRODUCTION Adoptive cell therapy (ACT) is considered to be one of the most effective immunotherapy methods for …
Planning a Phase 1 Clinical Trial: Target Product Profile for a …
2. T-cells are isolated through immunomagnetic cell separation. 3. T-cells are activated with antibodies and IL-2. 4. T-cells are transduced with a lentiviral vector to express the intended …
OPB-101: A mesothelin-specific CAR T cell therapy …
OPB-101: A mesothelin-specific CAR T cell therapy leveraging protein design to enhance T cell proliferation and persistence for the treatment of ovarian cancer Rupesh Amin, Kevin Haworth, …
BCL- 2 mutant B7H6- CAR- T cells synergized with venetoclax …
cancer promotes tumor progression, 17 18 anti- B7H6 CAR- T cell therapy decreases the tumor burden in lymphoma, melanoma, and ovarian cancer models.19 20 Notably, a clinical study …
INTERVIEW The Utlization of CAR-T therapy for Ovarian …
CELL THERAPY INSITS 288 DI 10.10cgti.01.0 In terms of effectiveness, the response rate, either complete or partial is usually somewhere around 60–80%. These tumors are usually pretty sen-
CAR-T cell immunotherapy for ovarian cancer
researchers have made arduous attempts to apply CAR-T therapy to ovarian cancer. In this review, we outline the principles of CAR-T therapy and then ... CAR-T cell immunotherapy for …
CAR-T Cell Therapy - AS ONE INT
CAR-T Introduction CAR-T Events CAR-T Cell Therapy Chimeric Antigen Receptor T cell therapy, or CAR-T cell therapy, has been widely used in the field of cancer immunotherapy and clinical …
Identification and Characterization of Fully Human FOLR1 …
Abstract: CAR T cell therapy has been an effective treatment option for hematological malignancies. ... nally, different ovarian cancer cell lines were employed as target cells in in …
“Advancing CAR T Cell Therapy for the Treatment of …
– Cancer stem cell–like phenotypes Ovarian Cancer CAR Targets: Aberrant Glycosylation Adapted from Reily et al., Nature Reviews, 2019 Hypothesis: Post-translational modification …
The Vascular Disrupting Agent CA4P Improves the Antitumor …
To explore the combined effect of CA4P and CAR-T cell therapy, we first generated CAR-T cells that specifically target HER2 (Fig-ure S1A),25 which is overexpressed in multiple types of …
Tuned activation of MSLN-CAR T cells induces superior …
MSLN-CAR T cells containing either CD28 (M28z) or 4-1BB (MBBz) costimulator y domain. 20 Functionality and therapeutic efficacy of M1xx CAR T cells was assessed in vitro and in two in …
CANCER copyright © 2025 The Mitigating T cell DNA …
CAR T cell therapy has the potential to address the immunosuppres-sive TME and inadequate CAR T cell infiltration into the tumor, po-tentially leading to active monitoring and continuous …
Engineered CAR-T cells targeting TAG-72 and CD47 in …
ally, Golubovskaya et al.31 have shown that anti-CD47 CAR-T cells could destroy multiple cancer cell lines in vitro, including ovarian cancer. In this study, we hypothesize that CAR-T cells with …
Research Paper Development of a CD39 nanobody and its …
CAR-T secreting bispecific T-cell engagers also exhibited improved efficacy against tumors [25,26]. Due to the elevated expression of CD39 in ovarian cancer and the tumor-targeting …
CD24 is a novel target of chimeric antigen receptor T cells for …
Keywords CD24 antigen · CAR-T cell therapy · Solid tumor · TNBC Introduction Breast cancer (BRCA) is the most common cancer in women in the world [1]. Triple negative breast cancer …
Combination therapy with CAR T cells and oncolytic viruses: …
REVIEW ARTICLE Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy Ramazan Rezaei 1, Hadi Esmaeili Gouvarchin Ghaleh , Mahdieh …
CAR macrophages tuning the immune symphony of anti …
antigen contact, unlike CAR-T cells, it is of high importance for CAR macrophage therapy to start with a sufficient cell yield. Consequently, multiple research groups have demonstrated …
Imaging CAR-NK cells targeted to HER2 ovarian cancer with …
such as the T cell receptor (TCR)/CD3 complex and the co-stimulatory domains 41BB or CD28 [12, 13]. Unlike tar-geted therapies that treat the biomarker/antigen of interest (e.g.,. …
Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell …
The cytotoxicity of NKG2Dz CAR-equipped Vg9Vd2 T cells was investigated against various types of human tumor cell lines, including NKG2DL-positive human HepG2 hepatocellular carci …
Anti-mesothelin CAR-T immunotherapy in patients with …
of our anti-MSLN CAR-T cells for ovarian cancer treatment in an in vitro experiment to kill ovarian tumor cell lines. The anti-MSLN CAR-T cells impeded MSLN-positive tumor growth …
TABLE OF CONTENTS - DTIC
Adoptive T-cell therapy, graft-versus-host disease, and γγγδγδ T cells. Allogeneic adoptive T-cell therapy (allo-ACT) is a cancer treatment modality used in clinical trials. Allo-ACT is particularly …
CAR T-CELL THERAPIES - Cancer
in patients with ovarian cancer 2010-11 Phase 1 clinical trial of CAR T-cells in chronic lymphoid leukemia, two of the three patients achieved complete remission ... The EMA to approve the …
Mesothelin-based CAR-T cells exhibit potent antitumor …
tumors from ovarian cancer cell in immunocompromised mice. Our results suggest that ligand-receptor-based CAR T cell therapy that is designed to exploit the interac - tion between …
Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell …
The cytotoxicity of NKG2Dz CAR-equipped Vg9Vd2 T cells was investigated against various types of human tumor cell lines, including NKG2DL-positive human HepG2 hepatocellular carci …
CAR T cell combination therapies to treat cancer - Cell Press
Various therapies under investigation in combination with CAR T cell therapy within clinical trials. These agents, through diverse mechanisms, offer potential ... Pancreatic cancer, ovarian …
Targeting the immune-suppressive tumor microenvironment …
T cell therapy against solid tumors such as prostate [28-30], ovarian [31-35], breast [36-39], pancreatic [40-44], and brain [45] cancers. ... Tang T (22) Targeting the immune-suppressive …
EZH1/EZH2 inhibition enhances adoptive T cell ... - Cell Press
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models Graphical abstract ... resistance and improving adoptive cell therapy outcomes. Porazzi et al., …
shRNA-mediated gene silencing of HDAC11 empowers CAR …
CAR-T cells (11). That is why, we speculated that interfering HDAC11 in CAR-T cells could be an excellent target to augment immunotherapeutic efficacy. Previous reports have showed that …
The application of HER2 and CD47 CAR-macrophage in …
stimulating T-cell activation [1]. CAR can combine with cancer cell surface antigen to induce and enhance the kill - ing eect of T cells on cancer cells [2]. In current research and clinical trials, …
CAR T-cell therapies in China: rapid evolution and a bright …
modest responses in patients with ovarian cancer, renal cancer, lymphoma, and neuroblastoma. 3–6. It was the introduction of co-stimulatory domains, particularly ... Since Wang and …
Pre-clinical evaluation of novel Folate Receptor 1 directed …
to identify target molecules for CAR T cell therapy in OvCa. Each specimen was exposed to a panel of fluorescently labeled antibodies by repeated cycles of antibody stain - ing, image …
World Journal of Surgery and Surgical Research
Chimeric Antigen Receptor-T (CAR-T) cell therapy is a novel cancer treatment that has been used in a variety of tumors. CAR-T cells can selectively and directly recognize and kill ... [23] …
intracellular tumor antigen WT1 secreting a bispecic T cell …
Pa ge 3/ 22 Abstract Epithelial ovarian cancer is the most lethal of gynecological cancers. The therapeutic ecacy of chimeric antigen receptor (CAR) T cell directed against single antigens is ...
Immunotherapy and Its Development for Gynecological …
Keywords: chimeric antigen receptor (CAR)-T cell therapy; lymphocytes; immunotherapy; ovarian cancer; endometrial cancer; cervical cancer 1. Introduction Gynecological tumors have a high …
The application of HER2 and CD47 CAR-macrophage in …
stimulating T-cell activation [1]. CAR can combine with cancer cell surface antigen to induce and enhance the kill - ing eect of T cells on cancer cells [2]. In current research and clinical trials, …
αPD-1-mesoCAR-T cells partially inhibit the growth of …
MSLN-positive ovarian cancer in vitro and in vivo.6 Existence of immunosuppressive pathways, especially the PD-1 and PD-L1 axis, can limit the full potential of adoptive T-cell therapy. …
Mesothelin CAR‐engineered NK cells derived from human …
tic target for CAR-NK cell therapy, considering its low expression on normal tissues and high expression in a broad spectrum of solid tumours. Particularly, high expression of MSLN is …
CAR-T therapy for endocrine neoplasms: novel targets and
T-cell depletion (27). A study conducted by Du and colleagues revealed promising application of B7-H3 CAR-T in ovarian cancer (OC), neuroblastoma and pancreatic cancer, without apparent …
Tuned activation of MSLN-CAR T cells induces superior …
MSLN-CAR T cells containing either CD28 (M28z) or 4-1BB (MBBz) costimulator y domain. 20 Functionality and therapeutic efficacy of M1xx CAR T cells was assessed in vitro and in two in …
